{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:15:10Z","timestamp":1793924110262,"version":"4.8.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Current evidence demonstrates that rigorous adherence to the standardized diagnostic and therapeutic protocols outlined in the European League Against Rheumatism (EULAR) guidelines can markedly enhance renal survival rates in patients with lupus nephritis (LN) and lead to improved overall outcomes. Data on the real-world implementation of LN management guideline in China was limited. This study aimed to examine the implementation of the 2023 EULAR recommendations for systemic lupus erymatosus (SLE) and LN in China.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Based on the Chinese Systemic Lupus Erythematosus Treatment and Research Group (CSTAR) cohort, patients with newly diagnosed active LN (24-h Urine Protein\u2009\u2265\u20090.5 g\/L) from April 2009 to March 2022 were included. The initial immunosuppressant therapy, the adjustment of immunosuppressant, and the implementation of renal biopsy at baseline were assessed. The patients\u2019 general conditions, clinical manifestations, the condition of rheumatologists and hospitals were included in the analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 1518 enrolled patients, 787 (52%) underwent cyclophosphamide or mycophenolate mofetil as the initial immunosuppressant, which was consistent with the EULAR recommendations. It was associated with longer disease duration, higher disease activity, more mucocutaneous involvement, and younger age of onset. Thirty out of 166 patients (18.1%) failed to achieve renal remission after 6 or 12 months of treatment, and 9 of whom had immunosuppressive therapy adjusted as recommended. Overall, 251 patients (16.5%) underwent renal biopsy at baseline, which were associated with significant renal involvement, unremarkable systemic involvement, and treated by senior rheumatologists.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Management of LN in China showed poor alignment with the 2023 EULAR recommendations regarding initial and adjusted therapy, as well as renal biopsy. The improvement of LN management requires both the patients and the rheumatologists to work together.\n<jats:table-wrap>\n                <jats:table>\n                  <jats:tbody>\n                    <jats:tr>\n                      <jats:td colspan=\"2\">\n                        <jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>To the best of our knowledge, this is the first real-world implementation study of LN in China. This is also the first real-world implementation study for the newly updated EULAR 2023 recommendation for SLE.<\/jats:italic>\u2022 <jats:italic>We not only examined the consistency between LN management in China and EULAR recommendations, but also identified potential factors associated with the implementation of the recommendations.<\/jats:italic>\u2022 <jats:italic>We believe that our study makes a significant contribution to the management of LN.<\/jats:italic>\n                      <\/jats:td>\n                    <\/jats:tr>\n                  <\/jats:tbody>\n                <\/jats:table>\n              <\/jats:table-wrap>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10067-025-07520-x","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T15:28:05Z","timestamp":1749310085000},"page":"2729-2739","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of newly diagnosed lupus nephritis in China: An implementation study based on the 2023 EULAR recommendations"],"prefix":"10.1007","volume":"44","author":[{"given":"Wei","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0617-6911","authenticated-orcid":false,"given":"Yinli","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuliang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"issue":"1","key":"7520_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","volume":"6","author":"HJ Anders","year":"2020","unstructured":"Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C (2020) Lupus nephritis. Nat Rev Dis Primers 6(1):7. https:\/\/doi.org\/10.1038\/s41572-019-0141-9","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"7520_CR2","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3899\/jrheum.101088","volume":"38","author":"X Feng","year":"2011","unstructured":"Feng X, Zou Y, Pan W et al (2011) Prognostic indicators of hospitalized patients with systemic lupus erythematosus: a large retrospective multicenter study in china. J Rheumatol 38(7):1289\u20131295. https:\/\/doi.org\/10.3899\/jrheum.101088","journal-title":"J Rheumatol"},{"issue":"2","key":"7520_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/acr.20683","volume":"64","author":"RW Jakes","year":"2012","unstructured":"Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N (2012) Systematic review of the epidemiology of systemic lupus erythematosus in the asia-pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken) 64(2):159\u2013168. https:\/\/doi.org\/10.1002\/acr.20683","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"7520_CR4","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/s0002-9343(02)01118-x","volume":"112","author":"VA Seligman","year":"2002","unstructured":"Seligman VA, Lum RF, Olson JL, Li H, Criswell LA (2002) Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med 112(9):726\u2013729. https:\/\/doi.org\/10.1016\/s0002-9343(02)01118-x","journal-title":"Am J Med"},{"issue":"2","key":"7520_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","volume":"55","author":"JG Hanly","year":"2016","unstructured":"Hanly JG, O\u2019Keeffe AG, Su L et al (2016) The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) 55(2):252\u2013262. https:\/\/doi.org\/10.1093\/rheumatology\/kev311","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"7520_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/1756-185X.12212","volume":"16","author":"CC Mok","year":"2013","unstructured":"Mok CC, Yap DY, Navarra SV et al (2013) Overview of lupus nephritis management guidelines and perspective from asia. Int J Rheum Dis 16(6):625\u2013636. https:\/\/doi.org\/10.1111\/1756-185X.12212","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"7520_CR7","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/1756-185X.13363","volume":"21","author":"Y Tanaka","year":"2018","unstructured":"Tanaka Y, Mizukami A, Kobayashi A, Ito C, Matsuki T (2018) Disease severity and economic burden in japanese patients with systemic lupus erythematosus: a retrospective, observational study. Int J Rheum Dis 21(8):1609\u20131618. https:\/\/doi.org\/10.1111\/1756-185X.13363","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"7520_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2478\/rir-2023-0022","volume":"4","author":"M Petri","year":"2023","unstructured":"Petri M, Fang C, Goldman DW (2023) East-asian lupus nephritis in the hopkins lupus cohort. Rheumatol Immunol Res 4(3):157\u2013161. https:\/\/doi.org\/10.2478\/rir-2023-0022","journal-title":"Rheumatol Immunol Res"},{"issue":"4","key":"7520_CR9","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.ekir.2024.01.016","volume":"9","author":"M Gatto","year":"2024","unstructured":"Gatto M, Frontini G, Calatroni M et al (2024) Effect of sustained clinical remission on the risk of lupus flares and impaired kidney function in patients with lupus nephritis. Kidney Int Rep 9(4):1047\u20131056. https:\/\/doi.org\/10.1016\/j.ekir.2024.01.016","journal-title":"Kidney Int Rep"},{"issue":"5","key":"7520_CR10","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/acr.20410","volume":"63","author":"TY Zhu","year":"2011","unstructured":"Zhu TY, Tam LS, Li EK (2011) Cost-of-illness studies in systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken) 63(5):751\u2013760. https:\/\/doi.org\/10.1002\/acr.20410","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"7520_CR11","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.3390\/ijerph20043522","volume":"20","author":"H Wang","year":"2023","unstructured":"Wang H, Li M, Zou K et al (2023) Annual direct cost and cost-drivers of systemic lupus erythematosus: a multi-center cross-sectional study from cstar registry. Int J Environ Res Public Health 20(4):3522. https:\/\/doi.org\/10.3390\/ijerph20043522","journal-title":"Int J Environ Res Public Health"},{"issue":"9","key":"7520_CR12","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/acr.23480","volume":"70","author":"M Barber","year":"2018","unstructured":"Barber M, Hanly JG, Su L et al (2018) Economic evaluation of lupus nephritis in the systemic lupus international collaborating clinics inception cohort using a multistate model approach. Arthritis Care Res (Hoboken) 70(9):1294\u20131302. https:\/\/doi.org\/10.1002\/acr.23480","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"7520_CR13","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1002\/acr.24092","volume":"72","author":"M Barber","year":"2020","unstructured":"Barber M, Hanly JG, Su L et al (2020) Economic evaluation of damage accrual in an international systemic lupus erythematosus inception cohort using a multistate model approach. Arthritis Care Res (Hoboken) 72(12):1800\u20131808. https:\/\/doi.org\/10.1002\/acr.24092","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"7520_CR14","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","volume":"71","author":"GK Bertsias","year":"2012","unstructured":"Bertsias GK, Tektonidou M, Amoura Z et al (2012) Joint european league against rheumatism and european renal association-european dialysis and transplant association (eular\/era-edta) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71(11):1771\u20131782. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201940","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"7520_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis A, Kostopoulou M, Cheema K et al (2020) 2019 update of the joint european league against rheumatism and european renal association-european dialysis and transplant association (eular\/era-edta) recommendations for the management of lupus nephritis. Ann Rheum Dis 79(6):713\u2013723. https:\/\/doi.org\/10.1136\/annrheumdis-2020-216924","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"7520_CR16","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J et al (2021) Executive summary of the kdigo 2021 guideline for the management of glomerular diseases. Kidney Int 100(4):753\u2013779. https:\/\/doi.org\/10.1016\/j.kint.2021.05.015","journal-title":"Kidney Int"},{"issue":"6","key":"7520_CR17","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A et al (2019) 2019 update of the eular recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78(6):736\u2013745. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215089","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7520_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/nep.12136","volume":"19","author":"CC Mok","year":"2014","unstructured":"Mok CC, Yap DY, Navarra SV et al (2014) Overview of lupus nephritis management guidelines and perspective from asia. Nephrology (Carlton) 19(1):11\u201320. https:\/\/doi.org\/10.1111\/nep.12136","journal-title":"Nephrology (Carlton)"},{"issue":"9","key":"7520_CR19","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3760\/cma.j.cn112138-20210609-00410","volume":"60","author":"H Zhang","year":"2021","unstructured":"Zhang H, Yang NS, Lu J et al (2021) recommendations for the diagnosis and management of lupus nephritis in china. Chinese Journal of Internal Medicine 60(9):784\u2013790. https:\/\/doi.org\/10.3760\/cma.j.cn112138-20210609-00410","journal-title":"Chinese Journal of Internal Medicine"},{"issue":"1","key":"7520_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J et al (2024) Eular recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83(1):15\u201329. https:\/\/doi.org\/10.1136\/ard-2023-224762","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"7520_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/1756-185X.12423","volume":"18","author":"DY Yap","year":"2015","unstructured":"Yap DY, Chan TM (2015) Treatment of lupus nephritis: practical issues in asian countries. Int J Rheum Dis 18(2):138\u2013145. https:\/\/doi.org\/10.1111\/1756-185X.12423","journal-title":"Int J Rheum Dis"},{"issue":"9","key":"7520_CR22","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC (1997) Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725. https:\/\/doi.org\/10.1002\/art.1780400928","journal-title":"Arthritis Rheum"},{"issue":"8","key":"7520_CR23","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai AM, Alarcon GS et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677\u20132686. https:\/\/doi.org\/10.1002\/art.34473","journal-title":"Arthritis Rheum"},{"issue":"9","key":"7520_CR24","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D et al (2019) 2019 european league against rheumatism\/american college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 71(9):1400\u20131412. https:\/\/doi.org\/10.1002\/art.40930","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"7520_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2478\/rir-2021-0025","volume":"2","author":"Z Wang","year":"2021","unstructured":"Wang Z, Li M, Ye Z et al (2021) Long-term outcomes of patients with systemic lupus erythematosus: a multicenter cohort study from cstar registry. Rheumatol Immunol Res 2(3):195\u2013202. https:\/\/doi.org\/10.2478\/rir-2021-0025","journal-title":"Rheumatol Immunol Res"},{"issue":"7","key":"7520_CR26","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1136\/annrheumdis-2021-221841","volume":"81","author":"S Jin","year":"2022","unstructured":"Jin S, Jiang N, Huo Y et al (2022) Management of rheumatoid arthritis in china: a study of the implementation of 2019 eular recommendations. Ann Rheum Dis 81(7):1052\u20131054. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221841","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7520_CR27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1573397114666180406100857","volume":"15","author":"CC Mok","year":"2019","unstructured":"Mok CC (2019) Is treat-to-target in lupus nephritis realistic in clinical practice? Curr Rheumatol Rev 15(1):2\u20136. https:\/\/doi.org\/10.2174\/1573397114666180406100857","journal-title":"Curr Rheumatol Rev"},{"issue":"6","key":"7520_CR28","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.21664","volume":"64","author":"BH Hahn","year":"2012","unstructured":"Hahn BH, Mcmahon MA, Wilkinson A et al (2012) American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64(6):797\u2013808. https:\/\/doi.org\/10.1002\/acr.21664","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"7520_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2478\/rir-2020-0009","volume":"1","author":"M Li","year":"2020","unstructured":"Li M, Zhao Y, Zhang Z et al (2020) 2020 chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus. Rheumatol Immunol Res 1(1):5\u201323. https:\/\/doi.org\/10.2478\/rir-2020-0009","journal-title":"Rheumatol Immunol Res"},{"key":"7520_CR30","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/OARRR.S248750","volume":"12","author":"L Bartels-Peculis","year":"2020","unstructured":"Bartels-Peculis L, Sharma A, Edwards AM, Sanyal A, Connolly-Strong E, Nelson WW (2020) Treatment patterns and health care costs of lupus nephritis in a united states payer population. Open Access Rheumatol 12:117\u2013124. https:\/\/doi.org\/10.2147\/OARRR.S248750","journal-title":"Open Access Rheumatol"},{"issue":"3","key":"7520_CR31","doi-asserted-by":"publisher","first-page":"e4437","DOI":"10.1136\/rmdopen-2024-004437","volume":"10","author":"M Pappa","year":"2024","unstructured":"Pappa M, Kosmetatou M, Pieta A et al (2024) Attainment of eular\/era-edta targets of therapy with current immunosuppressive regimens and adjustments in treatment: a multicentre, real-life observational study. RMD Open 10(3):e4437. https:\/\/doi.org\/10.1136\/rmdopen-2024-004437","journal-title":"RMD Open"},{"issue":"8","key":"7520_CR32","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/art.1780340803","volume":"34","author":"AD Steinberg","year":"1991","unstructured":"Steinberg AD, Steinberg SC (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34(8):945\u2013950. https:\/\/doi.org\/10.1002\/art.1780340803","journal-title":"Arthritis Rheum"},{"issue":"4","key":"7520_CR33","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","volume":"135","author":"GG Illei","year":"2001","unstructured":"Illei GG, Austin HA, Crane M et al (2001) Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135(4):248\u2013257. https:\/\/doi.org\/10.7326\/0003-4819-135-4-200108210-00009","journal-title":"Ann Intern Med"},{"issue":"12","key":"7520_CR34","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1002\/art.20666","volume":"50","author":"FA Houssiau","year":"2004","unstructured":"Houssiau FA, Vasconcelos C, D\u2019Cruz D et al (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the euro-lupus nephritis trial. Arthritis Rheum 50(12):3934\u20133940. https:\/\/doi.org\/10.1002\/art.20666","journal-title":"Arthritis Rheum"},{"issue":"8","key":"7520_CR35","first-page":"1563","volume":"33","author":"M Faurschou","year":"2006","unstructured":"Faurschou M, Starklint H, Halberg P, Jacobsen S (2006) Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol 33(8):1563\u20131569","journal-title":"J Rheumatol"},{"issue":"11","key":"7520_CR36","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1191\/0961203305lu2238oa","volume":"14","author":"G Contreras","year":"2005","unstructured":"Contreras G, Pardo V, Cely C et al (2005) Factors associated with poor outcomes in patients with lupus nephritis. Lupus 14(11):890\u2013895. https:\/\/doi.org\/10.1191\/0961203305lu2238oa","journal-title":"Lupus"},{"issue":"1","key":"7520_CR37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2215\/CJN.03280807","volume":"3","author":"YE Chen","year":"2008","unstructured":"Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ (2008) Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 3(1):46\u201353. https:\/\/doi.org\/10.2215\/CJN.03280807","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"7520_CR38","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1177\/0961203308090029","volume":"17","author":"FA Houssiau","year":"2008","unstructured":"Houssiau FA, Ginzler EM (2008) Current treatment of lupus nephritis. Lupus 17(5):426\u2013430. https:\/\/doi.org\/10.1177\/0961203308090029","journal-title":"Lupus"},{"issue":"8","key":"7520_CR39","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1136\/annrheumdis-2020-216965","volume":"79","author":"G Moroni","year":"2020","unstructured":"Moroni G, Gatto M, Tamborini F et al (2020) Lack of eular\/era-edta response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. Ann Rheum Dis 79(8):1077\u20131083. https:\/\/doi.org\/10.1136\/annrheumdis-2020-216965","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7520_CR40","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13075-024-03275-z","volume":"26","author":"PM Izmirly","year":"2024","unstructured":"Izmirly PM, Kim MY, Carlucci PM et al (2024) Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the accelerating medicines partnership lupus network. Arthritis Res Ther 26(1):54. https:\/\/doi.org\/10.1186\/s13075-024-03275-z","journal-title":"Arthritis Res Ther"},{"issue":"Suppl5","key":"7520_CR41","doi-asserted-by":"publisher","first-page":"v39","DOI":"10.1093\/rheumatology\/keaa381","volume":"59","author":"M Gasparotto","year":"2020","unstructured":"Gasparotto M, Gatto M, Binda V, Doria A, Moroni G (2020) Lupus nephritis: clinical presentations and outcomes in the 21st century. Rheumatology (Oxford) 59(Suppl5):v39\u2013v51. https:\/\/doi.org\/10.1093\/rheumatology\/keaa381","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"7520_CR42","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s10067-015-3003-1","volume":"34","author":"M Li","year":"2015","unstructured":"Li M, Tian X, Zhang W, Leng X, Zeng X (2015) Crdc: a chinese rheumatology research platform. Clin Rheumatol 34(8):1347\u20131352. https:\/\/doi.org\/10.1007\/s10067-015-3003-1","journal-title":"Clin Rheumatol"},{"issue":"6","key":"7520_CR43","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3760\/cma.j.cn112138-20220324-00206","volume":"61","author":"X Tian","year":"2022","unstructured":"Tian X, Li M, Zeng X (2022) The challenges and future development of the management of systemic lupus erythematosus in china: a concise annual report of 2020. Chin J Intern Med 61(6):611\u2013616. https:\/\/doi.org\/10.3760\/cma.j.cn112138-20220324-00206","journal-title":"Chin J Intern Med"},{"issue":"19","key":"7520_CR44","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1016\/j.scib.2024.04.075","volume":"69","author":"M Li","year":"2024","unstructured":"Li M, Li C, Cao M et al (2024) Incidence and prevalence of systemic lupus erythematosus in urban china, 2013\u20132017: a nationwide population-based study. Sci Bull (Beijing) 69(19):3089\u20133097. https:\/\/doi.org\/10.1016\/j.scib.2024.04.075","journal-title":"Sci Bull (Beijing)"},{"issue":"3","key":"7520_CR45","doi-asserted-by":"publisher","first-page":"162","DOI":"10.2478\/rir-2023-0023","volume":"4","author":"M Li","year":"2023","unstructured":"Li M, Tian X, Wang Q et al (2023) Improve quality of patient care for systemic lupus erythematosus in china by enhancing the construction of centers of excellence. Rheumatol Immunol Res 4(3):162\u2013166. https:\/\/doi.org\/10.2478\/rir-2023-0023","journal-title":"Rheumatol Immunol Res"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07520-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07520-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07520-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T07:46:23Z","timestamp":1751874383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07520-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7520"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07520-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involves human participants and was approved by the medical ethics committee of Peking Union Medical College Hospital (approval number: S-197). The participants gave informed consent to participate in the study before taking part.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and public involvement"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}